Letter to the Editor concerning ‘cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’

IF 1.5 4区生物学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnology & Biotechnological Equipment Pub Date : 2024-08-01 DOI:10.1080/13102818.2024.2386487

A. L. Stevenson, S. Chang-Douglass, P. Kazmierska, A. Benedict, K. Azimpour, P. Dorling

引用次数: 0

Abstract

Published in Biotechnology & Biotechnological Equipment (Vol. 38, No. 1, 2024)

查看原文本刊更多论文

致编辑的信，内容涉及 "轻度至中度α-甘露糖苷酶病患者接受 velmanase alfa 与骨髓移植或无因果关系疗法的成本效益对比

发表于《生物技术与生物技术设备》（第 38 卷第 1 期，2024 年）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology & Biotechnological Equipment 工程技术-生物工程与应用微生物

CiteScore

3.10

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Biotechnology & Biotechnological Equipment (B&BE) is an international open access journal publishing cutting-edge research. A modern world requires modern biotechnology and nanobiology. The journal is a forum that provides society with valuable information for a healthy and better life and promotes “the Science and Culture of Nature”. The journal publishes original research and reviews with a multidisciplinary perspective; expanded case reports with a focus on molecular medical research and advanced practice in evidence-based medicine are also considered.